Skip to main content
Fig. 2 | Antimicrobial Resistance & Infection Control

Fig. 2

From: Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

Fig. 2

Kaplan-Meier survival estimates among CRAB-BSI patients. a Kaplan-Meier survival estimates among CRAB-BSI patients with Tigecycline therapy and Cefoperazone/Sulbactam therapy. b Kaplan-Meier survival estimates among CRAB-BSI patients (APACHE II score < 20) with Tigecycline therapy and Cefoperazone/Sulbactam therapy. c Kaplan-Meier survival estimates among CRAB-BSI patients (APACHE II score ≥ 20) with Tigecycline therapy and Cefoperazone/Sulbactam therapy. Abbreviations: CRAB-BSI, Acinetobacter baumannii bloodstream infection; APACHE II score, acute physiology and chronic health evaluation II

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us